Stoke Therapeutics shares rise 1.91% after-hours following positive data presentation on zorevunersen dosing regimen.

Stoke Therapeutics, Inc. rose 1.91% in after-hours trading, following the announcement of data from an analysis that informed the design of the Phase 3 EMPEROR study and evaluated the potential effects of the Phase 3 zorevunersen dosing regimen. The data showed improvements within the first 9 months and continuing improvements through an additional two years, suggesting that this new genetically-targeted approach could address the underlying cause of Dravet syndrome.